ArticleDie Ophthalmologie2026
[Ophthalmological care of patients with Bardet-Biedl syndrome].
Article in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and research questionBardet-Biedl syndrome (BBS) is a rare genetic disorder characterized by a wide range of symptoms and clinical signs. The aim of the current work is to provide a comprehensive overview of the clinical and genetic features of BBS patients, with a focus on ophthalmological manifestations. MATERIAL AND
methodsIn a retrospective analysis at the University Eye Hospital Bonn, data from 18 patients with a molecular genetically confirmed diagnosis of BBS were analyzed. In addition to the medical history, clinical examination included multimodal imaging, the collection of functional data and molecular genetic diagnostics.
results17 patients (17/18; 94%) presented typical retinal changes consistent with retinitis pigmentosa (RP) and 1 patient (1/18; 6%) showed a central cone-rod dystrophy without peripheral changes. In addition, other nonophthalmological symptoms and clinical signs, such as limb abnormalities (9/18; 50%), obesity (7/18; 39%), urogenital tract abnormalities (7/18; 39%) and neurological symptoms (8/18; 44%) were noted. Molecular genetic analyses revealed disease-causing variants in several BBS genes, including the BBS1 (Bardet-Biedl syndrome)1 gene (9), BBS10 (3), BBS7 (1), BBS12 (1) and the MKKS (McKusick-Kaufmann syndrome) gene (2). The average time between the onset of the first ophthalmological symptoms and the final genetic diagnosis was 15 years (median 10 years, range 1-36 years).
conclusionThis study emphasizes the importance of an interdisciplinary approach in the diagnosis and treatment of BBS patients. The clinical heterogeneity of BBS can lead to diagnostic delays. Early diagnosis enables appropriate genetic counseling, monitoring of disease progression, individualized treatment initiation and exploration of potential therapeutic interventions.
Indexed as
Identifiers
41238926What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.